Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.
作者信息
Banerjee Rahul, Poh Christina, Hirayama Alexandre V, Gauthier Jordan, Cassaday Ryan D, Shadman Mazyar, Cowan Andrew J, Till Brian G, Green Damian J, Kiem Hans-Peter, Gopal Ajay K, Maloney David G
机构信息
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Department of Medicine, University of Washington, Seattle, WA.
出版信息
Blood Adv. 2024 Feb 27;8(4):895-898. doi: 10.1182/bloodadvances.2023012336.
Abstract
摘要
相似文献
1
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.解答临床中“医生，CAR-T疗法会引发癌症吗？”这一问题。
Blood Adv. 2024 Feb 27;8(4):895-898. doi: 10.1182/bloodadvances.2023012336.
2
Do cutting-edge CAR-T-cell therapies cause cancer? What the data say.前沿的嵌合抗原受体T细胞（CAR-T）疗法会引发癌症吗？数据说明了什么。
Nature. 2024 May;629(8010):22-24. doi: 10.1038/d41586-024-01215-0.
3
Chimeric Antigen Receptor (CAR) T-Cell Therapy.嵌合抗原受体（CAR）T细胞疗法
JAMA Oncol. 2017 Nov 1;3(11):1595. doi: 10.1001/jamaoncol.2017.2989.
4
Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.嵌合抗原受体修饰 T 细胞免疫治疗：一种新型细胞治疗方法，对临床实验室具有重要意义。
Clin Chem. 2019 Apr;65(4):519-529. doi: 10.1373/clinchem.2016.258988. Epub 2018 Dec 28.
5
Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.利用 CRISPR 基因组编辑技术构建强效嵌合抗原受体 T 细胞
Front Immunol. 2019 Mar 19;10:456. doi: 10.3389/fimmu.2019.00456. eCollection 2019.
6
Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy.CAR-T 细胞疗法：癌症治疗的革命
Med Oncol. 2023 Aug 22;40(9):275. doi: 10.1007/s12032-023-02146-y.
7
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.嵌合抗原受体（CAR）在癌症免疫疗法中的竞赛：从 CAR T、CAR NK 到 CAR 巨噬细胞疗法。
J Exp Clin Cancer Res. 2022 Mar 31;41(1):119. doi: 10.1186/s13046-022-02327-z.
8
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.实体瘤过继细胞免疫治疗：除 CAR-T 以外的方法
Mol Cancer. 2023 Feb 7;22(1):28. doi: 10.1186/s12943-023-01735-9.
9
CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.嵌合抗原受体 T 细胞疗法在癌症治疗中的困境与展望
J Immunol Res. 2020 Jan 17;2020:1924379. doi: 10.1155/2020/1924379. eCollection 2020.
10
Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.基于纳米颗粒的嵌合抗原受体疗法在癌症免疫治疗中的应用。
Tissue Eng Regen Med. 2023 Jun;20(3):371-387. doi: 10.1007/s13770-022-00515-8. Epub 2023 Mar 3.
引用本文的文献
1
Noncanonical and mortality-defining toxicities of CAR T cell therapy.嵌合抗原受体T细胞疗法的非典型及决定死亡率的毒性作用
Nat Med. 2025 Jul 16. doi: 10.1038/s41591-025-03813-5.
2
Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy.西达基奥仑赛治疗复发/难治性多发性骨髓瘤：疗效、安全性及治疗地位
Cancer Manag Res. 2025 Feb 19;17:357-372. doi: 10.2147/CMAR.S510408. eCollection 2025.
3
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.复发/难治性多发性骨髓瘤中标准治疗药物idecabtagene vicleucel与cilta-cabtagene autoleucel的比较。
J Clin Oncol. 2025 May;43(13):1597-1609. doi: 10.1200/JCO-24-01730. Epub 2025 Feb 18.
4
Celebrating a year of immunotherapy/cell and gene therapy in Blood Advances.庆祝《血液进展》中免疫疗法/细胞与基因疗法的一年。
Blood Adv. 2024 Dec 24;8(24):6334-6336. doi: 10.1182/bloodadvances.2024015305.
5
Better, Faster, Stronger: Accelerating mRNA-Based Immunotherapies With Nanocarriers.更好、更快、更强：纳米载体加速基于 mRNA 的免疫疗法。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Nov-Dec;16(6):e2017. doi: 10.1002/wnan.2017.
6
New horizons in our understanding of precursor multiple myeloma and early interception.在理解前驱性多发性骨髓瘤和早期干预方面的新进展。
Nat Rev Cancer. 2024 Dec;24(12):867-886. doi: 10.1038/s41568-024-00755-x. Epub 2024 Oct 16.
7
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma.嵌合抗原受体 T 细胞疗法治疗多发性骨髓瘤后免疫效应细胞相关肠炎。
Blood Cancer J. 2024 Oct 16;14(1):180. doi: 10.1038/s41408-024-01167-8.
8
The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?嵌合抗原受体 T 细胞疗法后继发性恶性肿瘤的现状：如何预防恶性肿瘤？
Int J Mol Sci. 2024 Sep 1;25(17):9518. doi: 10.3390/ijms25179518.
9
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.嵌合抗原受体 T 细胞（CAR T）治疗后第二原发恶性肿瘤：5517 例淋巴瘤和骨髓瘤患者的系统评价和荟萃分析。
Clin Cancer Res. 2024 Oct 15;30(20):4690-4700. doi: 10.1158/1078-0432.CCR-24-1798.
10
Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase.嵌合抗原受体（CAR）T细胞疗法后第二原发性恶性肿瘤的特征：来自FAERS和VigiBase这两个全球药物警戒数据库的真实世界见解
EClinicalMedicine. 2024 Jun 20;73:102684. doi: 10.1016/j.eclinm.2024.102684. eCollection 2024 Jul.
本文引用的文献
1
Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients.抗CD19嵌合抗原受体T细胞治疗患者中克隆性造血的临床意义及动态变化
Hemasphere. 2023 Oct 3;7(10):e957. doi: 10.1097/HS9.0000000000000957. eCollection 2023 Oct.
2
Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation.自体细胞移植后发生治疗相关急性髓系白血病和骨髓增生异常综合征的多发性骨髓瘤患者的特征和结局。
Transplant Cell Ther. 2024 Feb;30(2):205.e1-205.e12. doi: 10.1016/j.jtct.2023.06.015. Epub 2023 Jul 10.
3
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.阿基仑赛治疗大 B 细胞淋巴瘤的总生存。
N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5.
4
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.西达基奥仑赛或标准护理用于来那度胺难治性多发性骨髓瘤。
N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5.
5
Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.自体移植后第二原发恶性肿瘤对多发性骨髓瘤结局的影响：CIBMTR 分析。
Blood Adv. 2023 Jun 27;7(12):2746-2757. doi: 10.1182/bloodadvances.2022009138.
6
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.伊达赛利珠单抗或标准方案治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.
7
Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering.新型外显基因安全港，用于精确的治疗性 T 细胞工程。
Blood. 2023 Jun 1;141(22):2698-2712. doi: 10.1182/blood.2022018924.
8
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.自体抗 BCMA 嵌合抗原受体 T 细胞（liso-cel）治疗二线弥漫大 B 细胞淋巴瘤（DLBCL）的 3 期 TRANSFORM 研究的主要分析结果
Blood. 2023 Apr 6;141(14):1675-1684. doi: 10.1182/blood.2022018730.
9
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.ZUMA-7 研究中的患者报告结局，该研究是一项评估 axicabtagene ciloleucel 在二线大 B 细胞淋巴瘤中的 3 期研究。
Blood. 2022 Nov 24;140(21):2248-2260. doi: 10.1182/blood.2022015478.
10
Patient preferences for treatment in relapsed/refractory diffuse large B-cell lymphoma: a discrete choice experiment.患者对复发/难治性弥漫性大 B 细胞淋巴瘤治疗的偏好：一项离散选择实验。
Future Oncol. 2022 Aug;18(25):2791-2804. doi: 10.2217/fon-2022-0421. Epub 2022 Jul 15.
Zotero 插件